Indivior Plc - ADR
INVVY
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.3B
Close$
Share Statistics
| Market cap | $4.30 Billion |
|---|---|
| Enterprise Value | $4.62 Billion |
| Dividend Yield | $0.64 (-) |
| Earnings per Share | $1.68 |
| Beta | -0.06 |
| Outstanding Shares | 125,352,000 |
Return
| Return on Equity | -171.15% |
|---|---|
| Return on Assets | 28.87% |
| Return on Invested Capital | 117.53% |
Valuation & Multiples
| P/E Ratio | 12.14 |
|---|---|
| PEG | 2.1 |
| Price to Sales | 2.18 |
| Price to Book Ratio | -10.92 |
| Enterprise Value to Revenue | 3.47 |
| Enterprise Value to EBIT | 10.76 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -2.59 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...